AUTHOR=Rao Amanda , Clayton Paul , Briskey David 

TITLE=Libifem® (Trigonella foenum-graecum) in conjunction with exercise on muscle strength, power, endurance, and body composition in females aged between 25 and 45 years

JOURNAL=Frontiers in Sports and Active Living

VOLUME=5

YEAR=2023

URL=https://www.frontiersin.org/journals/sports-and-active-living/articles/10.3389/fspor.2023.1207013

DOI=10.3389/fspor.2023.1207013

ISSN=2624-9367

ABSTRACT=<sec><title>Introduction</title><p>This study examined the effects of <italic>Libifem</italic>® on exercise performance and body composition in females 25–45 years old.</p></sec><sec><title>Methods</title><p>Participants were randomized to three equal groups to consume: 600 mg <italic>Libifem</italic>®/day, 300 mg <italic>Libifem</italic>®/day or a placebo for 8 weeks. Participants completed a whole-body exercise program three times a week for 8 weeks. At baseline, week 4 and week 8, muscle strength and endurance, functional threshold power, body composition, and sex hormones were measured. At week 8, all three groups increased leg press 1RM compared to baseline.</p></sec><sec><title>Results</title><p>A significant difference between group treatment effect was seen for leg press at week 8 (<italic>p</italic> = 0.045), with the 600 mg <italic>Libifem</italic>® group significantly increasing their leg press 1RM compared to placebo (<italic>p</italic> = 0.014). The 600 mg <italic>Libifem</italic>® group significantly reduced their total fat mass (0.96 kg loss) from baseline compared to placebo group (0.09 kg gain). There was no significant difference in fat mass for the 300 mg <italic>Libifem</italic>® group (0.23 kg loss). The 600 mg <italic>Libifem</italic>® group had a significant increase in lean mass compared to both the 300 mg and placebo groups (<italic>p</italic> = 0.011 and 0.009, respectively).</p></sec><sec><title>Discussion</title><p>Overall, there were significant and dose-related changes in body composition and ergogenic parameters, comparable with previous findings in males.
</p></sec><sec><title>Clinical Trial Registration</title><p>This trial was registered with the Australian and New Zealand Clinical Trials registry [ACTRN12618001538235].</p></sec>